astrazeneca-sign

AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer

pharmafile | June 27, 2019 | News story | Research and Development AstraZeneca, Imfinzi, pharma 

AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell lung cancer (SCLC), illustrating that the therapy met its primary endpoint in a planned interim analysis carried out by an independent data monitoring committee.

The results of the analysis demonstrated that use of Imfinzi, combined with standard-of-care etoposide and platinum-based chemotherapy in the first-line setting, led to a “statistically significant and clinically meaningful” improvement in overall survival (OS) compared to chemotherapy alone.

Following this analysis, the trial will now continue to further assess the impact on OS in combination with tremelimumab and chemotherapy.

The condition SCLC is an area with significant unmet need, and patients only have access to a handful of treatment options, making these results all the more impactful for affected patients.

Advertisement

“The Phase 3 CASPIAN results offer new hope for patients who are facing the devastating diagnosis of small cell lung cancer, and for whom new medicines are urgently needed,” commented José Baselga, Executive Vice President, Oncology R&D at AstraZeneca. “This is the first trial offering the flexibility of combining immunotherapy with different platinum-based regimens in small cell lung cancer, expanding treatment options.”

The company also announced that it will present these findings in full at an upcoming medical meeting.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content